Just elaborating from my previous post regarding some of the...

Just elaborating from my previous post regarding some of the potential that Noxopharm may hold regarding the LUPUS presentation announcement dated 22 February 2023

Noxopharm CEO Dr Gisela Mautner said: “To be recognised at such a high-profile
conference is a great outcome that reflects the promising nature of the SofraTM platform.
We are working in close collaboration with the Hudson Institute team on these novel
therapeutics, and believe that our findings will receive considerable attention from
scientists and other biotech companies. There is growing interest in the potential of
oligonucleotides to open up new pathways to treatments for a wide range of diseases, and
numerous industry participants are looking to complement or add to their existing portfolios
as the technology continues to evolve.”